Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tissue inhibitor of metalloproteinases-1 (TIMP-1) is a secreted 28-kDa glycoprotein that plays a pivotal role in regulating the extracellular matrix (ECM) by acting as a natural, stoichiometric inhibitor of most active matrix metalloproteinases (MMPs). By forming tight 1:1 non-covalent complexes with the catalytic zinc cofactor of target MMPs, TIMP-1 controls ECM turnover, tissue remodeling, and wound healing. Beyond its classical protease-inhibitory function, TIMP-1 acts as a multifunctional cytokine and growth factor, engaging cell-surface receptors such as CD63, integrin β1, and CD74 to trigger intracellular signaling pathways (e.g., AKT and MAPK) that promote cell proliferation, survival, and anti-apoptotic responses. Dysregulation of TIMP-1 is strongly implicated in various pathologies, including cancer progression, metastasis, tissue fibrosis, and cardiovascular diseases. Consequently, TIMP-1 is a valuable prognostic biomarker (such as in the Enhanced Liver Fibrosis score) and an attractive therapeutic target. Current drug development strategies focus on downregulating TIMP-1 expression in fibrotic conditions, neutralizing its signaling in oncology, or engineering selective TIMP-1 variants to target specific MMPs while avoiding the musculoskeletal toxicities historically associated with broad-spectrum metalloproteinase inhibitors.
Modulation of TIMP-1 expression (such as downregulation by tipelukast), neutralization of TIMP-1 signaling using monoclonal antibodies, or the use of engineered TIMP-1 variants as selective inhibitors of specific matrix metalloproteinases.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tissue inhibitor of metalloproteinases-1 (TIMP-1).